<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035668</url>
  </required_header>
  <id_info>
    <org_study_id>CLOU064E12201</org_study_id>
    <secondary_id>2018-004387-54</secondary_id>
    <nct_id>NCT04035668</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome</brief_title>
  <acronym>LOUiSSe</acronym>
  <official_title>An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      LOU064 is an oral Bruton's tyrosine kinase (BTK) inhibitor. This study is an adaptive phase 2
      study designed to establish safety and efficacy and characterize the dose-response of LOU064
      in subjects with moderate to severe Sjögren's syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2019</start_date>
  <completion_date type="Anticipated">August 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in EULAR Sjögren's syndrome disease activity index (ESSDAI) at week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Efficacy (Clinical Outcome Measures)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ESSDAI over time</measure>
    <time_frame>Baseline, week 2, week 4, week 8, week 12, week 16 and week 20</time_frame>
    <description>Efficacy (Clinical Outcome Measures)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EULAR Sjögren's Syndrome Patient Reported intensity (ESSPRI) over time</measure>
    <time_frame>24 weeks</time_frame>
    <description>Efficacy (Patient Reported Outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) over time</measure>
    <time_frame>24 weeks</time_frame>
    <description>Efficacy (Patient Reported Outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life as assessed by EQ-5D over time</measure>
    <time_frame>24 weeks</time_frame>
    <description>Efficacy (Patient Reported Outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life as assessed by PhGA over time</measure>
    <time_frame>24 weeks</time_frame>
    <description>Efficacy (Patient Reported Outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of treatment emergent Adverse Events</measure>
    <time_frame>34 weeks</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: area under the curve (AUC)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: Cmax</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: Tmax</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: mean residence time (MRT)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Sjögren Syndrome</condition>
  <arm_group>
    <arm_group_label>LOU064 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LOU064 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LOU064 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>middle orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LOU064 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 mg orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOU064</intervention_name>
    <description>10mg hard gelatin capsules 25mg hard gelatin capsules 50mg hard gelatin capsules</description>
    <arm_group_label>LOU064 Dose 1</arm_group_label>
    <arm_group_label>LOU064 Dose 2</arm_group_label>
    <arm_group_label>LOU064 Dose 3</arm_group_label>
    <arm_group_label>LOU064 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0mg hard gelatin capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of SjS according to the 2016 ACR/EULAR criteria

          -  Screening ESSDAI (based on weighted score) ≥ 5 derived from 8 domains

          -  Screening ESSPRI ≥ 5

          -  Seropositive for anti-Ro/SSA antibodies at or within 3 months prior to screening

          -  Unstimulated salivary flow &gt; 0 mL/min.

        Exclusion Criteria:

          -  Sjögren's Syndrome overlap syndromes with another autoimmune disease as primary
             illness

          -  DMARDs or kinase inhibitors within 3 months prior to baseline above certain doses OR
             maintained during study

          -  Rituximab or other B cell depleting drug within 12 months of Screening .

          -  Current use of prednisone or equivalent &gt; 15mg/d or dose change within 2 weeks prior
             to Screening

          -  Use of medication known to cause, as a major side effect, dry mouth / eyes

          -  HIV, Hepatitis C, Hepatitis B, known or suspected history of an ongoing, chronic or
             recurrent infectious disease such as tuberculosis

        Other protocol-defined inclusion/exclusion criteria may apply at the end
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81346</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Swindon</city>
        <zip>SN3 6BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sjogren Syndrome</keyword>
  <keyword>Dry Eye Syndromes</keyword>
  <keyword>Pathological Processes</keyword>
  <keyword>Arthritis, Rheumatoid</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Joint Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Rheumatic Diseases</keyword>
  <keyword>Xerostomia</keyword>
  <keyword>Salivary Gland Diseases</keyword>
  <keyword>Mouth Diseases</keyword>
  <keyword>Stomatognathic Diseases</keyword>
  <keyword>Lacrimal Apparatus Diseases</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>Connective Tissue Diseases</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

